Arcturus Therapeutics Holdings Inc. (ARCT) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Arcturus Therapeutics is a global mRNA medicines company focused on infectious disease vaccines and rare diseases in the liver and respiratory systems. The company operates as a single segment focused on research and development. Key assets include the STARR self-amplifying mRNA technology and the LUNAR lipid-mediated delivery system. The company's COVID-19 vaccine, ARCT-154 (Kostaive), received marketing authorization in Japan in 2023.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $49,859 | $10,519 | $87,871 | $90,804 |
| Net Loss | $(17,216) | $(52,550) | $(44,033) | $(1,796) |
| Net Loss Per Share | $(0.64) | $(1.98) | $(1.64) | $(0.07) |
| Operating Expenses | $70,985 | $65,893 | $139,409 | $131,423 |
| Cash & Restricted Cash | $317,214 | $380,598 | $317,214 | $380,598 |
| Accumulated Deficit | $(411,899) | $(339,937) | $(411,899) | $(339,937) |
Liquidity: As of June 30, 2024, the company held $260.3 million in cash and cash equivalents and $56.9 million in restricted cash. Management believes current resources are sufficient to fund operations for at least the next twelve months. The company has a $50.0 million revolving credit facility with Wells Fargo, which was amended in June 2024 to extend the term to April 2026; no borrowings were outstanding as of the reporting date.
Material Changes vs. Prior Period
- Revenue Surge in Q2: Q2 2024 revenue increased by $39.3 million (374%) compared to Q2 2023. This was driven primarily by a $17.0 million development milestone achieved under the CSL Seqirus collaboration and the recognition of revenue from a supply agreement. Collaboration revenue from CSL Seqirus was $45.9 million in Q2 2024 versus $7.6 million in Q2 2023.
- YTD Revenue Decline: For the six months ended June 30, 2024, total revenue decreased by $2.9 million (3.2%) compared to the prior year. This decrease was due to lower milestone achievements in the first half of 2024 compared to 2023, partially offset by a $7.8 million increase in BARDA grant revenue.
- Expense Growth: Research and development (R&D) expenses increased by $6.0 million (11.4%) in Q2 2024, primarily due to increased clinical and manufacturing costs. General and administrative expenses decreased slightly by $0.9 million.
- Net Loss Improvement: The net loss for Q2 2024 narrowed significantly to $17.2 million from $52.6 million in Q2 2023, largely due to the revenue spike and higher interest income ($4.1 million vs $3.3 million).
Guidance, Outlook, and Risks
Outlook and Pipeline:
- CSL Seqirus Collaboration: The company continues to advance COVID-19 and influenza vaccine programs. A Phase 3 study for the bivalent ARCT-2301 vaccine met its primary endpoint in Japan. A Phase 3 study for the XBB1.5 variant (ARCT-2303) is ongoing in the Southern Hemisphere with results expected in Q4 2024.
- Rare Disease Programs: The Phase 2 study for ARCT-810 (OTC deficiency) completed enrollment. The Phase 1b study for ARCT-032 (Cystic Fibrosis) showed safety and tolerability, with an IND application for a Phase 2 study submitted in July 2024.
- Regulatory: The European Medicines Agency (EMA) is reviewing the marketing authorization application for ARCT-154.
Risks and Contingencies:
- Material Weaknesses in Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in Information Technology General Controls (ITGCs) and revenue recognition controls. Remediation is ongoing and expected to be completed in fiscal year 2024.
- Liquidity Risk: The company has incurred significant losses since inception and expects to continue doing so. Future funding requirements depend on milestone achievements, clinical trial success, and the ability to secure additional financing.
- Collaboration Dependence: A significant portion of revenue and future potential is tied to the CSL Seqirus agreement. Delays in milestones or regulatory approvals could materially impact financial results.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of remediation plans for the identified material weaknesses in ITGCs and revenue recognition controls.
- CSL Seqirus Milestone Timing: Confirm the timing of the $17.0 million milestone payment received in Q2 and the status of future milestone triggers under the collaboration agreement.
- Cash Burn Rate: Monitor the net cash used in operating activities ($35.7 million for the six months ended June 30, 2024) against the $317.2 million cash balance to assess runway.
- Regulatory Filings: Track the status of the EMA review for ARCT-154 and the results of the Phase 3 XBB1.5 study expected in Q4 2024.
- Debt Facility Status: Confirm the terms of the amended Wells Fargo credit facility and ensure no covenant breaches occur given the company's loss position.